RT Journal Article
SR Electronic
T1 Longitudinal peripheral blood transcriptional analysis of COVID-19 patients captures disease progression and reveals potential biomarkers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20091355
DO 10.1101/2020.05.05.20091355
A1 Yan, Qihong
A1 Li, Pingchao
A1 Ye, Xianmiao
A1 Huang, Xiaohan
A1 Mo, Xiaoneng
A1 Wang, Qian
A1 Zhang, Yudi
A1 Luo, Kun
A1 Chen, Zhaoming
A1 Luo, Jia
A1 Niu, Xuefeng
A1 Feng, Ying
A1 Ji, Tianxing
A1 Feng, Bo
A1 Wang, Jinlin
A1 Li, Feng
A1 Zhang, Fuchun
A1 Li, Fang
A1 Wang, Jianhua
A1 Feng, Liqiang
A1 Chen, Zhilong
A1 Lei, Chunliang
A1 Qu, Linbing
A1 Chen, Ling
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.05.20091355.abstract
AB COVID-19, caused by SARS-CoV-2, is an acute self-resolving disease in most of the patients, but some patients can develop a severe illness or even death. To characterize the host responses and identify potential biomarkers during disease progression, we performed a longitudinal transcriptome analysis for peripheral blood mononuclear cells (PBMCs) collected from 4 COVID-19 patients at 4 different time points from symptom onset to recovery. We found that PBMCs at different COVID-19 disease stages exhibited unique transcriptome characteristics. SARS-CoV-2 infection dysregulated innate immunity especially type I interferon response as well as the disturbed release of inflammatory cytokines and lipid mediators, and an aberrant increase of low-density neutrophils may cause tissue damage. Activation of cell death, exhaustion and migratory pathways may lead to the reduction of lymphocytes and dysfunction of adaptive immunity. COVID-19 induced hypoxia may exacerbate disorders in blood coagulation. Based on our analysis, we proposed a set of potential biomarkers for monitoring disease progression and predicting the risk of severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (82041014 and 81661148056), the Chinese Academy of Sciences Pilot Strategic Science and Technology Projects (XDB29050701).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw RNA-seq data used in this study have been deposited at the National Genomics Data Center (https://bigd.big.ac.cn/) under the accession number: PRJCA002599. All scripts used in this study are publicly available at https://github.com/ChenLinglab/.